{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:08:10Z","timestamp":1779084490817,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,17]]},"DOI":"10.7759\/cureus.109066","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:49:01Z","timestamp":1779083341000},"source":"Crossref","is-referenced-by-count":0,"title":["A Rare Case of Pulmonary Arterial Hypertension in a Patient With Breast Cancer Treated With Trastuzumab Emtansine"],"prefix":"10.7759","author":[{"given":"Abbie","family":"Maggs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyad","family":"Elmarzouky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysovalantou","family":"Nikolaidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: presentation, investigation and management","volume":"83","author":"Katsura C","year":"2022","unstructured":"Katsura C, Ogunmwonyi I, Kankam HK, Saha S. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond). 2022, 83:1-7. 10.12968\/hmed.2021.0459","journal-title":"Br J Hosp Med (Lond)"},{"key":"ref2","unstructured":"Breast Cancer UK. Facts and figures. (2024). Accessed. January 12, 2026: https:\/\/www.breastcanceruk.org.uk\/about-breast-cancer\/facts-figures-and-qas\/facts-and-figures."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206779","article-title":"Biologic and therapeutic role of HER2 in cancer","volume":"22","author":"M\u00e9nard S","year":"2003","unstructured":"M\u00e9nard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003, 22:6570-8. 10.1038\/sj.onc.1206779","journal-title":"Oncogene"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/crst.crst_134_22","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"5","author":"Ganguly S","year":"2022","unstructured":"Ganguly S, Gogia A. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. Cancer Res Stat Treat. 2022, 5:393. 10.4103\/crst.crst_134_22","journal-title":"Cancer Res Stat Treat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al.. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367:1783-91. 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok M","year":"2014","unstructured":"Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014, 16:209. 10.1186\/bcr3621","journal-title":"Breast Cancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s J","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, et al.. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022, 386:1143-54. 10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.09.008","article-title":"Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine: a case report","volume":"149","author":"Kwon Y","year":"2016","unstructured":"Kwon Y, Gomberg-Maitland M, Pritzker M, Thenappan T. Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine: a case report. Chest. 2016, 149:e103-5. 10.1016\/j.chest.2015.09.008","journal-title":"Chest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00199-2020","article-title":"Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data","volume":"6","author":"Umoru G","year":"2020","unstructured":"Umoru G, Taitano M, Beshay S, Niravath P, Sahay S. Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data. ERJ Open Res. 2020, 6:00199-2020. 10.1183\/23120541.00199-2020","journal-title":"ERJ Open Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2023.3013","article-title":"Cancer therapy-related pulmonary hypertension: a review of mechanisms and implications for clinical practice","volume":"27","author":"G\u00fcrdo\u011fan M","year":"2023","unstructured":"G\u00fcrdo\u011fan M, Demir M, Yalta K, G\u00fclertop Y. Cancer therapy-related pulmonary hypertension: a review of mechanisms and implications for clinical practice. Anatol J Cardiol. 2023, 27:299-307. 10.14744\/AnatolJCardiol.2023.3013","journal-title":"Anatol J Cardiol"},{"key":"ref11","article-title":"Identifying new drugs associated with pulmonary arterial hypertension: a WHO pharmacovigilance database disproportionality analysis","volume":"88","author":"Hlavaty A","year":"2025","unstructured":"Hlavaty A, Roustit M, Montani D, et al.. Identifying new drugs associated with pulmonary arterial hypertension: a WHO pharmacovigilance database disproportionality analysis. Br J Clin Pharmacol. 2025, 88:5227-37.","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.11.006","article-title":"Association of pulmonary hypertension with trastuzumab emtansine: an analysis of French Pulmonary Hypertension Registry and WHO Pharmacovigilance Database","volume":"167","author":"Poisson C","year":"2025","unstructured":"Poisson C, Hlavaty A, Favrolt N, et al.. Association of pulmonary hypertension with trastuzumab emtansine: an analysis of French Pulmonary Hypertension Registry and WHO Pharmacovigilance Database. Chest. 2025, 167:1468-80. 10.1016\/j.chest.2024.11.006","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/479290-a-rare-case-of-pulmonary-arterial-hypertension-in-a-patient-with-breast-cancer-treated-with-trastuzumab-emtansine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:49:05Z","timestamp":1779083345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/479290-a-rare-case-of-pulmonary-arterial-hypertension-in-a-patient-with-breast-cancer-treated-with-trastuzumab-emtansine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.109066","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,17]]}}}